Celyad Oncology S.A.
CLYYFOTCHealthcare● Active
$0.25
+$0.00(+0.00%)
Market Cap$11190476
P/E Ratio—
52W High$0.53
52W Low$0.15
Celyad Oncology S.A. (CLYYF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CLYYF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 2, 2026EPS Actual
-$0.13
Revenue
$0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 2, 2026
After Market Close
✓ 2-Quarter EPS Beat Streak
CLYYF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 23, 2026 | — | — | — | — | — | — |
| — Q2 FY2026 | Apr 2, 2026 | — | -$0.13 | — | $0.00B | — | — |
| — Q1 FY2026 | Mar 25, 2026 | — | $0.13 | — | $0.00B | — | — |
| — Q3 FY2025 | Sep 25, 2025 | — | -$0.10 | — | $0.00B | — | — |
| — Q2 FY2025 | Apr 2, 2025 | — | -$0.07 | — | $0.00B | — | — |
| ▲ Q2 FY2024 | Apr 4, 2024 | -$0.86 | -$0.18 | +79.2% | $0.00B | — | — |
| ▲ Q2 FY2023 | Jun 30, 2023 | -$0.87 | -$0.18 | +79.3% | $0.00B | — | — |
| ▼ Q1 FY2023 | Mar 23, 2023 | -$0.87 | -$1.28 | -47.8% | — | — | — |
Q3 FY2026
Sep 23, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 2, 2026
EPS Actual
-$0.13
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2026
Mar 25, 2026
EPS Actual
$0.13
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2025
Sep 25, 2025
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
Apr 2, 2025
EPS Actual
-$0.07
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2024
Apr 4, 2024Beat
EPS Actual
-$0.18
EPS Est.
-$0.86
EPS Surpr.
+79.2%
Revenue
$0.00B
Q2 FY2023
Jun 30, 2023Beat
EPS Actual
-$0.18
EPS Est.
-$0.87
EPS Surpr.
+79.3%
Revenue
$0.00B
Q1 FY2023
Mar 23, 2023Miss
EPS Actual
-$1.28
EPS Est.
-$0.87
EPS Surpr.
-47.8%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | Apr 2, 2026 | — | $0.35 | $0.35 | +0.00% |
| — Q1 FY2026 | Mar 25, 2026 | — | $0.35 | $0.35 | +0.00% |
| — Q3 FY2025 | Sep 25, 2025 | — | $0.41 | $0.41 | +0.00% |
| — Q2 FY2025 | Apr 2, 2025 | — | $0.65 | $0.65 | +0.00% |
| ▲ Q2 FY2024 | Apr 4, 2024 | +79.2% | $0.36 | $0.32 | -12.01% |
| ▲ Q2 FY2023 | Jun 30, 2023 | +79.3% | $0.52 | $0.54 | +3.59% |
| ▼ Q1 FY2023 | Mar 23, 2023 | -47.8% | $0.25 | $0.52 | +109.40% |
| ▲ Q2 FY2022 | Jun 30, 2022 | +65.2% | No price data | $0.25 | — |
Q2 FY2026+0.00%
Report Date
Apr 2, 2026
EPS Beat/Miss
—
Price Before
$0.35
Price After
$0.35
Q1 FY2026+0.00%
Report Date
Mar 25, 2026
EPS Beat/Miss
—
Price Before
$0.35
Price After
$0.35
Q3 FY2025+0.00%
Report Date
Sep 25, 2025
EPS Beat/Miss
—
Price Before
$0.41
Price After
$0.41
Q2 FY2025+0.00%
Report Date
Apr 2, 2025
EPS Beat/Miss
—
Price Before
$0.65
Price After
$0.65
Q2 FY2024-12.01%
Report Date
Apr 4, 2024
EPS Beat/Miss
+79.2%
Price Before
$0.36
Price After
$0.32
Q2 FY2023+3.59%
Report Date
Jun 30, 2023
EPS Beat/Miss
+79.3%
Price Before
$0.52
Price After
$0.54
Q1 FY2023+109.40%
Report Date
Mar 23, 2023
EPS Beat/Miss
-47.8%
Price Before
$0.25
Price After
$0.52
Q2 FY2022—
Report Date
Jun 30, 2022
EPS Beat/Miss
+65.2%
Price Before
—
Price After
$0.25
Avg Beat Reaction-4.21%
Avg Miss Reaction+109.40%
Beat Rate3 / 8 quarters
Largest Move+109.40% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CLYYF ends December
Celyad Oncology S.A. (CLYYF) most recently reported earnings on April 2, 2026 for Q2 FY2026, posting EPS of $-0.13 (in line with the analyst consensus of —). CLYYF has beaten EPS estimates for 2 consecutive quarters. The next CLYYF earnings date is expected around September 1, 2026.
Each quarter, investors track CLYYF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CLYYF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CLYYF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CLYYF earnings · 4 questionsCelyad Oncology S.A.'s next earnings report is expected around September 1, 2026. CLYYF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CLYYF historically reports after market close (AMC).
CLYYF earnings datewhen is CLYYF earningsCLYYF next earnings datewhen does CLYYF report earningsCLYYF earnings calendar
▸ Source: FMP · Celyad Oncology S.A. SEC filings · US GAAP · Celyad Oncology S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026